AP NEWS

Global Endocrinology Drugs Market Report 2018 - Forecast to 2022 Featuring Leading Vendors - Abbvie, Merck, Novo Nordisk & Pfizer - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Global Endocrinology Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Endocrinology Drugs Market to grow at a CAGR of 6.48% during the period 2018-2022.

Global Endocrinology Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of endocrinology drugs.

According to the report, one driver influencing this market is the increasing incidence of endocrine disorders. The increase in incidence of endocrine disorders may be due to the rising aging population globally. A trend that is generally seen in the incidence of endocrinology disorders such as diabetes is that the incidence is generally higher in low-and middle-income countries.

The use of biosimilars for endocrine disorders to be one of the major trends in the market A biosimilar is a biologic product that is approved based on demonstrating that it is similar to an approved biologic product, known as a reference product.

Further, the report states that one challenge affecting this market is the reimbursement challenges. Most endocrine disorders pose a significant economic burden on patients as well as on healthcare systems. Physicians and patients have concerns regarding inadequate reimbursement for most endocrine disorders, including diabetes.

Key vendors

Abbvie Merck Novo Nordisk Pfizer

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 08: MARKET SEGMENTATION BY THERAPY AREA

Comparison by therapy area Diabetes drugs Thyroid hormone disorder drugs hGH Testosterone replacement therapy Others Market opportunity by therapy area

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Association between obesity and endocrine disorders Use of biosimilars for endocrine disorders

PART 14: VENDOR LANDSCAPE

Overview Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/2fp76n/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926005849/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 01:36 PM/DISC: 09/26/2018 01:36 PM

http://www.businesswire.com/news/home/20180926005849/en

AP RADIO
Update hourly